At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oxytocin to Reduce Stress-induced Craving in Individuals With Opioid Use Disorder
In Brief
A Phase 1 clinical trial evaluating intranasal oxytocin, 40 IU, twice a day for 7 days for Opioid Use Disorder. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Although stress has long been linked to substance use, craving and relapse, there are no available medications that target stress-induced substance use disorder (SUD). In particular, with the rise in opioid use, there is still a crucial need for developing effective pharmacological treatments that target and integrate the complexity of this disease. The long term goal of this project is to identify the key neuroendocrine pathways that are responsible for stress-induced craving in individuals with opioid use disorder (OUD) in order to better understand how they can be effectively treated.
Study Details
Timeline
Interventions
Adjunct therapy